2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology 2016, 144: 146-152. PMID: 27894751, PMCID: PMC5183545, DOI: 10.1016/j.ygyno.2016.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarboplatinCarcinomaCD4 Lymphocyte CountCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell SurvivalDisease-Free SurvivalDNA Polymerase IIDrug Resistance, NeoplasmEndometrial NeoplasmsFemaleHumansMicrosatellite InstabilityMiddle AgedMutationPoly-ADP-Ribose Binding ProteinsTumor Cells, CulturedConceptsBetter prognosisTumor cell linesInfiltration of CD4Number of CD4Platinum-based chemotherapyT lymphocyte infiltrationPD-1 receptorCell linesLow metastatic capabilityPOLE-mutated tumorsWild-type ECsEC cell linesLymphocyte infiltrationFavorable prognosisPD-1EC patientsType tumorsEnhanced immunogenicityT lymphocytesMolecular subtypesTumors correlatesChemotherapyMetastatic capabilityPrognosisTumors
2015
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients
Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecologic Oncology 2015, 138: 11-17. PMID: 25931171, PMCID: PMC4469551, DOI: 10.1016/j.ygyno.2015.04.027.Peer-Reviewed Original ResearchConceptsCytotoxic T lymphocytesCancer patientsPole tumorsT cellsHigher IFN-γ expressionLevels of CD8Endometrial cancer patientsTumor-specific CD4T cell responsesEndometrial cancer cellsIFN-γ expressionHelper armCTL responsesEndometrial cancerFavorable prognosisBetter prognosisEndometrial carcinomaLymphoid subsetsNaïve CD4T lymphocytesTumor extractsCD4CD8Immune systemCell responsesImproved survival of patients with hypermutation in uterine serous carcinoma
Santin AD, Bellone S, Centritto F, Schlessinger J, Lifton R. Improved survival of patients with hypermutation in uterine serous carcinoma. Gynecologic Oncology Reports 2015, 12: 3-4. PMID: 26076146, PMCID: PMC4442647, DOI: 10.1016/j.gore.2015.01.005.Peer-Reviewed Original Research
2012
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Review Of Anticancer Therapy 2012, 12: 41-49. PMID: 22149431, PMCID: PMC3287395, DOI: 10.1586/era.11.192.Peer-Reviewed Original ResearchConceptsType II endometrial cancerUterine serous cancerEndometrial cancerSerous cancerAggressive variantType I endometrial cancerFemale genital malignanciesUterine serous carcinomaOlder patientsGenital malignanciesMost recurrencesBetter prognosisSerous carcinomaEndometrial tumorsAggressive subsetEarly diagnosisTherapeutic markersMost carcinomasCancerCarcinomaMarkersHypertensionPostmenopausalObesityPatients
2011
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy
ElSahwi KS, Santin AD. erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstetrics And Gynecology International 2011, 2011: 128295. PMID: 21876697, PMCID: PMC3159302, DOI: 10.1155/2011/128295.Peer-Reviewed Original ResearchUterine serous adenocarcinomaERBB2 overexpressionEndometrial cancerCommon female genital tract malignancyFemale genital tract malignanciesType I endometrial cancerGenital tract malignanciesUterine serous cancerViable treatment optionSerous cancerStandard chemotherapyWorse survivalLymph nodesTrastuzumab therapyBetter prognosisDistant metastasisSerous adenocarcinomaTreatment optionsCase reportRecurrent casesBreast cancerHumanized mAbTrastuzumab activityType II variantCancer relapse